Natera (NASDAQ:NTRA) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

NTRA has been the subject of a number of other research reports. BidaskClub lowered shares of Virtu Financial from a sell rating to a strong sell rating in a research report on Wednesday, June 12th. Piper Jaffray Companies set a $40.00 target price on shares of Tapestry and gave the stock a buy rating in a research report on Monday, June 10th. Finally, Canaccord Genuity restated an average rating on shares of Kellogg in a research report on Tuesday, June 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $30.14.

NTRA opened at $26.10 on Wednesday. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73. The stock has a 50 day moving average price of $25.27. Natera has a 1-year low of $11.08 and a 1-year high of $29.62.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.05. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. The firm had revenue of $66.82 million during the quarter, compared to analyst estimates of $66.40 million. Equities research analysts anticipate that Natera will post -2.17 earnings per share for the current fiscal year.

In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the transaction, the chairman now owns 1,286,612 shares in the company, valued at $31,895,111.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the transaction, the insider now owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. Insiders have sold 5,311 shares of company stock valued at $132,287 in the last quarter. 9.29% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can raised its stake in shares of Natera by 136.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 3,420 shares during the period. Legal & General Group Plc raised its stake in shares of Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the period. Focused Wealth Management Inc purchased a new stake in shares of Natera in the second quarter valued at $83,000. BNP Paribas Arbitrage SA raised its stake in shares of Natera by 827.1% in the first quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 7,047 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Natera by 431.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 9,636 shares during the period. Institutional investors and hedge funds own 80.27% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.